Gustavo Pinheiro Santana
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Gustavo Pinheiro Santana has a total of 49 co-authors. Here are the top co-authors by number of shared publications:
- Caio Rebouças Fonseca Cafezeiro
Hospital Ana Nery
2 shared publications - Fernanda Pinheiro Martin Tapioca
Hospital Ana Nery
2 shared publications - Jackson Pedro Barros-Pereira
Hospital Ana Nery
2 shared publications - Luiz Carlos Santana Passos
Hospital Ana Nery
2 shared publications Tainá Teixeira Viana
2 shared publications- William Carvalho
Hospital Ana Nery
2 shared publications
Latest Publications
- Open Access
- 1 October 2024
- Published by Sociedade Brasileira de Cardiologia in ABC Heart Failure & Cardiomyopathy
- Vol. 4 (2)
De Novo Versus Upgrade Cardiac Resynchronization Therapy in Patients with Heart Failure: A Cohort Study
Background: Cardiac resynchronization therapy (CRT) is beneficial for patients with heart failure (HF) who have left bundle branch block. However, the benefits of CRT in patients with prior cardiac stimulation remain uncertain. Objective: Compare short-term mortality between upgrade and de novo CRT implantation. Methods: This prospective cohort study included patients with HF indicated for CRT with left ventricular ejection fraction (LVEF) below 35%. Overall survival was assessed using the Kaplan–Meier method, and multivariate analysis was performed using a Cox [...] Abstract Background: Cardiac resynchronization therapy (CRT) is beneficial for patients with heart failure (HF) who have left bundle branch block. However, the benefits of CRT in patients with prior cardiac stimulation remain uncertain. Objective: Compare short-term mortality between upgrade and de novo CRT implantation. Methods: This prospective cohort study included patients with HF indicated for CRT with left ventricular ejection fraction (LVEF) below 35%. Overall survival was assessed using the Kaplan–Meier method, and multivariate analysis was performed using a Cox
- 1 October 2024
- Published by Sociedade Brasileira de Cardiologia in ABC Heart Failure & Cardiomyopathy
- Vol. 4 (2)
Open AccessDe Novo Versus Upgrade Cardiac Resynchronization Therapy in Patients with Heart Failure: A Cohort Study
Background: Cardiac resynchronization therapy (CRT) is beneficial for patients with heart failure (HF) who have left bundle branch block. However, the benefits of CRT in patients with prior cardiac stimulation remain uncertain. Objective: Compare short-term mortality between upgrade and de novo CRT implantation. Methods: This prospective cohort study included patients with HF indicated for CRT with left ventricular ejection fraction (LVEF) below 35%. Overall survival was assessed using the Kaplan–Meier method, and multivariate analysis was performed using a Cox [...] Abstract Background: Cardiac resynchronization therapy (CRT) is beneficial for patients with heart failure (HF) who have left bundle branch block. However, the benefits of CRT in patients with prior cardiac stimulation remain uncertain. Objective: Compare short-term mortality between upgrade and de novo CRT implantation. Methods: This prospective cohort study included patients with HF indicated for CRT with left ventricular ejection fraction (LVEF) below 35%. Overall survival was assessed using the Kaplan–Meier method, and multivariate analysis was performed using a Cox
- Open Access
- 30 September 2024
- Published by Sociedade Brasileira de Cardiologia in ABC Heart Failure & Cardiomyopathy
- Vol. 4 (2)
Terapia de Ressincronização Cardíaca de Novo versus Upgrade em Pacientes com Insuficiência Cardíaca: Estudo de Coorte
Fundamento: A terapia de ressincronização cardíaca (TRC) traz benefícios para pacientes com insuficiência cardíaca (IC) que apresentam bloqueio de ramo esquerdo. No entanto, os benefícios da TRC em pacientes com estimulação cardíaca prévia ainda são incertos. Objetivo: Comparar a mortalidade de curto prazo entre o upgrade e a implantação de TRC de novo. Métodos: Estudo de coorte prospectiva que incluiu pacientes com IC indicados para TRC com fração de ejeção do ventrículo esquerdo (FEVE) inferior a 35%. A sobrevida global foi avaliada pelo método de Kaplan-Meier, e a análise multivariada foi realizada utilizando o modelo de regressão de Cox. Resultados: Foram avaliados 412 pacientes com um acompanhamento médio de 59 ± 8 meses. Destes, 104 pacientes estiveram no grupo upgrade enquanto 308 pacientes foram incluídos grupo de novo. A doença de Chagas foi a causa mais prevalente de IC, com 148 casos (36%). Enquanto o grupo de novo cursou com aumento da FEVE (de 25% ± 6,7% para 28% ± 16,3%, p = 0,005), os pacientes que realizaram upgrade não apresentaram diferença estatística na FEVE aos 6 meses (de 27,5% ± 6,9% para 27,5% ± 15,5%, p = 0,6). A mortalidade global em 1 ano foi de 122 casos (29,6%). Em análise multivariada, apenas FEVE e upgrade de TRC permaneceram independentemente associadas ao desfecho (hazard ratio: 0,93, intervalo de confiança: 0,90 a 0,97, p = 0,001; hazard ratio: 2,90, intervalo de confiança: 1,21 a 7,10, p = 0,002, respectivamente). Conclusão: Nesta população de IC, o grupo upgrade foi associado à maior mortalidade em 1 ano quando comparado com o grupo de novo.
- 30 September 2024
- Published by Sociedade Brasileira de Cardiologia in ABC Heart Failure & Cardiomyopathy
- Vol. 4 (2)
Open AccessTerapia de Ressincronização Cardíaca de Novo versus Upgrade em Pacientes com Insuficiência Cardíaca: Estudo de Coorte
Fundamento: A terapia de ressincronização cardíaca (TRC) traz benefícios para pacientes com insuficiência cardíaca (IC) que apresentam bloqueio de ramo esquerdo. No entanto, os benefícios da TRC em pacientes com estimulação cardíaca prévia ainda são incertos. Objetivo: Comparar a mortalidade de curto prazo entre o upgrade e a implantação de TRC de novo. Métodos: Estudo de coorte prospectiva que incluiu pacientes com IC indicados para TRC com fração de ejeção do ventrículo esquerdo (FEVE) inferior a 35%. A sobrevida global foi avaliada pelo método de Kaplan-Meier, e a análise multivariada foi realizada utilizando o modelo de regressão de Cox. Resultados: Foram avaliados 412 pacientes com um acompanhamento médio de 59 ± 8 meses. Destes, 104 pacientes estiveram no grupo upgrade enquanto 308 pacientes foram incluídos grupo de novo. A doença de Chagas foi a causa mais prevalente de IC, com 148 casos (36%). Enquanto o grupo de novo cursou com aumento da FEVE (de 25% ± 6,7% para 28% ± 16,3%, p = 0,005), os pacientes que realizaram upgrade não apresentaram diferença estatística na FEVE aos 6 meses (de 27,5% ± 6,9% para 27,5% ± 15,5%, p = 0,6). A mortalidade global em 1 ano foi de 122 casos (29,6%). Em análise multivariada, apenas FEVE e upgrade de TRC permaneceram independentemente associadas ao desfecho (hazard ratio: 0,93, intervalo de confiança: 0,90 a 0,97, p = 0,001; hazard ratio: 2,90, intervalo de confiança: 1,21 a 7,10, p = 0,002, respectivamente). Conclusão: Nesta população de IC, o grupo upgrade foi associado à maior mortalidade em 1 ano quando comparado com o grupo de novo.
- Open Access
- 4 April 2024
- Published by Elsevier in Structural Heart
- Vol. 8 (4) , 100298
Impact of Tricuspid Repair on Surgical Death in Patients Undergoing Mitral Valve Surgery Due to Rheumatic Disease
- 4 April 2024
- Published by Elsevier in Structural Heart
- Vol. 8 (4) , 100298
Open AccessImpact of Tricuspid Repair on Surgical Death in Patients Undergoing Mitral Valve Surgery Due to Rheumatic Disease
- Open Access
- 24 February 2023
- Published by Wiley
Upgrade is independently associated with short-term mortality after cardiac resynchronization therapy.
Title: Upgrade is independently associated with short-term mortality after cardiac resynchronization therapy.
- 24 February 2023
- Published by Wiley
Open AccessUpgrade is independently associated with short-term mortality after cardiac resynchronization therapy.
Title: Upgrade is independently associated with short-term mortality after cardiac resynchronization therapy.
- Open Access
- 1 February 2023
- Published by Wiley
Impact of Preoperative Pulmonary Hypertension on Early Surgical Death in Patients Undergoing Mitral Valve Surgery due to Rheumatic Diseas
Objective: In a population of patients undergoing cardiac surgery for rheumatic mitral valve disease, evaluate the impact of preoperative PH on early surgical mortality. Methods: This is a prospective cohort carried out from January 1, 2017 to December 30, 2020. All patients over 18 years of age who underwent cardiac surgery to correct rheumatic mitral valve disease with functional tricuspid regurgitation in an echocardiogram performed up to 6 months before surgery were included. Systolic pulmonary artery pressure (sPAP) value was also defined by preoperative echocardiogram evaluation. The primary outcome was surgical mortality. Results: 144 patients were included. The mean age was 46.2 (±12.3) years with 107 (74.3%) female individuals, the median left ventricular ejection fraction was 61.0% (55 - 67) and sPAP was 55.0 mmHg (46 - 74), with 45 (31.3%) individuals with right ventricular dysfunction. The predominant valve disease was mitral stenosis (74.3%). The prevalence of severe tricuspid regurgitation was 47.2%. The total in-hospital mortality was 15 (10.4%) individuals. sPAP was independently associated with early surgical death RR 1.04 (1.01 – 1.07), p = 0.003. To determine a sPAP cut-off that indicates higher mortality and help decision making in clinical practice, we performed an analysis through the ROC curve (area 0.70, p=0.012). The estimated value of 73.5mmHg has the highest accuracy in our model for predicting early mortality. Conclusion: In patients with rheumatic heart disease who will undergo mitral valve surgery, pulmonary hypertension is associated with higher early mortality. Values above 73.5 mmHg predict higher risk and, in this part of the population, additional measures to control intraoperative and immediate postoperative pulmonary hypertension should be considered.
- 1 February 2023
- Published by Wiley
Open AccessImpact of Preoperative Pulmonary Hypertension on Early Surgical Death in Patients Undergoing Mitral Valve Surgery due to Rheumatic Diseas
Objective: In a population of patients undergoing cardiac surgery for rheumatic mitral valve disease, evaluate the impact of preoperative PH on early surgical mortality. Methods: This is a prospective cohort carried out from January 1, 2017 to December 30, 2020. All patients over 18 years of age who underwent cardiac surgery to correct rheumatic mitral valve disease with functional tricuspid regurgitation in an echocardiogram performed up to 6 months before surgery were included. Systolic pulmonary artery pressure (sPAP) value was also defined by preoperative echocardiogram evaluation. The primary outcome was surgical mortality. Results: 144 patients were included. The mean age was 46.2 (±12.3) years with 107 (74.3%) female individuals, the median left ventricular ejection fraction was 61.0% (55 - 67) and sPAP was 55.0 mmHg (46 - 74), with 45 (31.3%) individuals with right ventricular dysfunction. The predominant valve disease was mitral stenosis (74.3%). The prevalence of severe tricuspid regurgitation was 47.2%. The total in-hospital mortality was 15 (10.4%) individuals. sPAP was independently associated with early surgical death RR 1.04 (1.01 – 1.07), p = 0.003. To determine a sPAP cut-off that indicates higher mortality and help decision making in clinical practice, we performed an analysis through the ROC curve (area 0.70, p=0.012). The estimated value of 73.5mmHg has the highest accuracy in our model for predicting early mortality. Conclusion: In patients with rheumatic heart disease who will undergo mitral valve surgery, pulmonary hypertension is associated with higher early mortality. Values above 73.5 mmHg predict higher risk and, in this part of the population, additional measures to control intraoperative and immediate postoperative pulmonary hypertension should be considered.
- Open Access
- 29 November 2022
- Published by Wiley
Indexing of left atrial volume by body surface area and height in a Brazilian population without previous heart disease and with a normal heart on echocardiography. Behavior in obese and overweight patients.
Background: Left atrial (LA) volume indexing for body surface area (BSA) may underestimate LA size in obese and overweight people. Since LA volume is a risk marker for some cardiovascular events, it is suggested that indexing for height would be an alternative more apropriated method. The aims of this study were to find normal and the best cutoff values for LA volume indexed for height in our population. Methods: Echocardiograms from 2018 to 2021 were reviewed and patients without known cardiac disease and completely normal echocardiograms that had the left atrial volume (LAvol) measured by biplane Simpson’s method were included. LAvol was indexed by BSA (ml/m²), by height (LAvol/m), by height raised to exponent 2.7 (ml/ m2.7) and by height squared (ml/h²). Results: A total of 545 patients, 50.5 ± 13.4 y., 335 females (61,5%) were analyzed. There were 145 normal weight (26.6%), 215 overweight (39.4%), 154 obese (28.3%) and 31 low weight (5.7%) patients. To estabilish normal values we included only the normal weight group and considered normal values from 2SD below to 2SD above the mean. Mean and normal values were: LAvol/h 26.0 ±4.5, 17 – 30 ml/m, LAvol/ht² 16 ± 2.8, 10.4 - 21.6 ml/ ht² and LAvol/ht2.7 11.4 ± 2.2, 7.0 - 15.8 ml/m2.7. The normal LAvol/ht2.7 differed between male and female (11.4 ± 2.4 and 12.8 ± 2.6, p = 0.000). LA diameter, LAvol, LAvol/h, LAvol/h² and LAvol/ht2.7 increased progressively from low-weight, normal weight, overweight and obese patients (p= 0.0000), but not LAvol/BSA. When indexing LAvol for height, for height² and for height2.7 20.8%, 22.7% and 21.4% of the obese patients, respectively, were reclassified as enlarged LA, and 7.4%, 8.8% and 8.4% of the overweight patients as well. Using ROC curve analysis, LAvol/h² had the highest AUC ant the best predictive value to identify LA enlargement and LAvol/BSA the worst one. Conclusions: normal values for LAvol indexed for height by three different methods are described in normal individuals. We reinforce that LAvol indexation for BSA underestimates LA size in obese and overweight patients and in these groups, specially, indexing for height² is probably the best method to evaluate LAvol.
- 29 November 2022
- Published by Wiley
Open AccessIndexing of left atrial volume by body surface area and height in a Brazilian population without previous heart disease and with a normal heart on echocardiography. Behavior in obese and overweight patients.
Background: Left atrial (LA) volume indexing for body surface area (BSA) may underestimate LA size in obese and overweight people. Since LA volume is a risk marker for some cardiovascular events, it is suggested that indexing for height would be an alternative more apropriated method. The aims of this study were to find normal and the best cutoff values for LA volume indexed for height in our population. Methods: Echocardiograms from 2018 to 2021 were reviewed and patients without known cardiac disease and completely normal echocardiograms that had the left atrial volume (LAvol) measured by biplane Simpson’s method were included. LAvol was indexed by BSA (ml/m²), by height (LAvol/m), by height raised to exponent 2.7 (ml/ m2.7) and by height squared (ml/h²). Results: A total of 545 patients, 50.5 ± 13.4 y., 335 females (61,5%) were analyzed. There were 145 normal weight (26.6%), 215 overweight (39.4%), 154 obese (28.3%) and 31 low weight (5.7%) patients. To estabilish normal values we included only the normal weight group and considered normal values from 2SD below to 2SD above the mean. Mean and normal values were: LAvol/h 26.0 ±4.5, 17 – 30 ml/m, LAvol/ht² 16 ± 2.8, 10.4 - 21.6 ml/ ht² and LAvol/ht2.7 11.4 ± 2.2, 7.0 - 15.8 ml/m2.7. The normal LAvol/ht2.7 differed between male and female (11.4 ± 2.4 and 12.8 ± 2.6, p = 0.000). LA diameter, LAvol, LAvol/h, LAvol/h² and LAvol/ht2.7 increased progressively from low-weight, normal weight, overweight and obese patients (p= 0.0000), but not LAvol/BSA. When indexing LAvol for height, for height² and for height2.7 20.8%, 22.7% and 21.4% of the obese patients, respectively, were reclassified as enlarged LA, and 7.4%, 8.8% and 8.4% of the overweight patients as well. Using ROC curve analysis, LAvol/h² had the highest AUC ant the best predictive value to identify LA enlargement and LAvol/BSA the worst one. Conclusions: normal values for LAvol indexed for height by three different methods are described in normal individuals. We reinforce that LAvol indexation for BSA underestimates LA size in obese and overweight patients and in these groups, specially, indexing for height² is probably the best method to evaluate LAvol.